Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-22-000095
Filing Date
2022-06-06
Accepted
2022-06-06 20:09:02
Documents
1
Period of Report
2022-06-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_165456052861515.html 4  
1 FORM 4 wf-form4_165456052861515.xml 4 6170
  Complete submission text file 0001714899-22-000095.txt   7567
Mailing Address AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE MA 02139
Business Address
Cole Douglas G. (Reporting) CIK: 0001486373 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 22999540

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)